tibljТуберкулез и болезни легкихTuberculosis and Lung Diseases2075-12302542-1506Медицинские знания и технологии10.21292/2075-1230-2020-98-4-6-14tiblj-1412Research ArticleОБЗОРREVIEWНовая коронавирусная инфекцияNovel coronavirus infectionhttps://orcid.org/0000-0003-4339-126XВеселоваЕ. И.VeselovaE. I.

Веселова Елена Игоревна научный сотрудник отдела инфекционной патологии

Elena I. Veselova Researcher of Infectious Pathology Department

drveselovae@mail.ruРусскихА. Е.RusskikhA. E.

Русских Анастасия Евгеньевна научный сотрудник

Anastasia E. Russkikh Researcher

ana-lobach@yandex.ruКаминскийГ. Д.KaminskiyG. D.

Каминский Григорий Дмитриевич доктор медицинских наук, руководитель отдела инфекционной патологии

Grigoriy D. Kaminskiy Doctor of Medical Sciences, Head of Infectious Pathology Department

gregkaminski.gk@gmail.comhttps://orcid.org/0000-0002-3091-4677ЛовачеваО. В.LovachevaO. V.

Ловачева Ольга Викторовна доктор медицинских наук, профессор, главный научный сотрудник

Olga V. Lovacheva Doctor of Medical Sciences, Professor, Head Researcher

olga.lovacheva@yandex.ruhttps://orcid.org/0000-0001-6596-9777СамойловаА. Г.SamoylovaA. G.

Самойлова Анастасия Геннадьевна доктор медицинских наук, первый заместитель директора

Anastasiya G. Samoylova Doctor of Medical Sciences, First Deputy Director

a.samoilova.nmrc@mail.ruhttps://orcid.org/0000-0002-0637-7955ВасильеваИ. А.VasilyevaI. A.

Васильева Ирина Анатольевна доктор медицинских наук, профессор, директор

Irina A. Vasilyeva Doctor of Medical Sciences, Professor, Director

nmrc@nmrc.ruФГБУ «Национальный медицинский исследовательский центр фтизиопульмонологии и инфекционных заболеваний» МЗ РФРоссияNational Medical Research Center of Phthisiopulmonology and Infectious DiseasesRussian Federation202006052020984614Copyright © Веселова Е.И., Русских А.Е., Каминский Г.Д., Ловачева О.В., Самойлова А.Г., Васильева И.А., 20202020Веселова Е.И., Русских А.Е., Каминский Г.Д., Ловачева О.В., Самойлова А.Г., Васильева И.А.Veselova E.I., Russkikh A.E., Kaminskiy G.D., Lovacheva O.V., Samoylova A.G., Vasilyeva I.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.tibl-journal.com/jour/article/view/1412

В обзоре проанализировано 59 источников литературы, в которых отражены известные на данный момент аспекты этиологии, патогенеза, диагностики и лечения заболевания COVID-19, вызванного коронавирусом SARS-CoV-2.

Авторы заявляют об отсутствии у них конфликта интересов.

The article presents the review of 59 publications describing the aspects of etiology, pathogenesis, diagnostics, and treatment of COVID-19 caused by SARS-CoV-2 coronavirus.

The authors state that they have no conflict of interests.

заболевание COVID-19коронавирус SARS-CoV-2этиологияпатогенездиагностикалечениеCOVID-19SARS-CoV-2 coronavirusetiologypathogenesisdiagnosticstreatmentReferencesАрсеньев А. Новые рычаги опухолевого сопротивления: Lag-3, Tim-3, TIGIT. 2019. https://medach.pro/post/1831.Arseniev A. Novye rychagi opukholevogo soprotivleniya: Lag-3, Tim-3, TIGIT. [New tools for tumor suppression: Lag-3, Tim-3, TIGIT]. 2019. https://medach.pro/post/1831.Электронный ресурс. – http://windtreetx.investorroom.com/2020-03-24-Windtree-to-Pursue-Clinical-Study-of-Lung-Injury-Treatment-in-COVID-19-Patients-with-its-KL4-Surfactant-Therapy.(Epub.), http://windtreetx.investorroom.com/2020-03-24-Windtree-to-Pursue-Clinical-Study-of-Lung-Injury-Treatment-in-COVID-19-Patients-with-its-KL4-Surfactant-Therapy.Abdulamir A. S., Hafidh R. R. The possible immunological pathways for the variable immunopathogenesis of COVID-19 infections among healthy adults, elderly and children // Electron. J. Gen. Med. ‒ 2020. ‒ Vol. 17, № 4. ‒ Р. em202.Abdulamir A.S., Hafidh R.R. The possible immunological pathways for the variable immunopathogenesis of COVID-19 Infections among healthy adults, elderly and children. Electron. J. Gen. Med., 2020, vol. 17, no. 4, pp. em202.Benetti E. et al. ACE2 variants underlie interindividual variability and susceptibility to COVID-19 in Italian population. – medRxiv. 03.04.2020.Benetti E. et al. ACE2 variants underlie interindividual variability and susceptibility to COVID-19 in Italian population. medRxiv, 03.04.2020.Caly L., Druce J. D., Catton M. G., Jans D. A., Wagstaff K. M. The FDA approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro // Antiviral. Research. ‒ 2020.Caly L., Druce J.D., Catton M.G., Jans D.A., Wagstaff K.M. The FDA approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral. Research, 2020.Cao B., Wang Y., Wen D., Liu W., Wang J., Fan G. et al. A trial of Lopinavir-Ritonavir in adults hospitalized with severe Covid-19 // New Engl. J. Med. ‒ 2020.Cao B., Wang Y., Wen D., Liu W., Wang J., Fan G. et al. A trial of Lopinavir-Ritonavir in adults hospitalized with severe Covid-19. New Engl. J. Med., 2020.Cao Y. C., Deng Q. X., Dai S. X. Remdesivir for Severe Acute Respiratory Syndrome Coronavirus 2 Causing COVID-19: An Evaluation of the Evidence // Travel. Med. Infect. Dis. ‒ 2020. ‒ Apr 2; 101647.Cao Y.C., Deng Q.X., Dai S.X. Remdesivir for Severe Acute Respiratory Syndrome Coronavirus 2 Causing COVID-19: An Evaluation of the Evidence. Travel. Med. Infect. Dis., 2020, Apr 2; 101647.Chen W., Lan Y., Yuan X. et al. Detectable 2019-nCoV Viral RNA in blood is a strong indicator for the further clinical severity // Emerg. Microbes. Infect. ‒ 2020. ‒ Vol. 9, № 1. ‒ Р. 469-473.Chen W., Lan Y., Yuan X. et al. Detectable 2019-nCoV Viral RNA in blood is a strong indicator for the further clinical severity. Emerg. Microbes. Infect., 2020, vol. 9, no. 1, pp. 469-473.Cortegiani A., Ingoglia G., Ippolito M., Giarratano A., Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19 // J. Crit. Care. ‒ 03.2020.Cortegiani A., Ingoglia G., Ippolito M., Giarratano A., Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J. Crit. Care, 03.2020.Diao B., Wang C., Tan Y., Chen X. et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). medRxiv 2020.Diao B., Wang C., Tan Y., Chen X. et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). medRxiv 2020.Dolhnikoff M., Duarte-Neto A. N., de Almeida Monteiro R. A., Ferraz da Silva L. F. Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19. https://onlinelibrary.wiley.com/doi/epdf/10.1111/jth.14844.Dolhnikoff M., Duarte-Neto A.N., de Almeida Monteiro R.A., Ferraz da Silva L.F. Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19. https://onlinelibrary.wiley.com/doi/epdf/10.1111/jth.14844.Elfiky A. A. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19 // Life Sci. ‒ 2020.Elfiky A.A. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci., 2020.Fahmi M., Kubota Y., Ito M. Nonstructural proteins NS7b and NS8 are likely to be phylogenetically associated with evolution of 2019-nCoV // Infect. Genet. Evol. ‒ 2020.Fahmi M., Kubota Y., Ito M. Nonstructural proteins NS7b and NS8 are likely to be phylogenetically associated with evolution of 2019-nCoV. Infect. Genet. Evol., 2020.Fang L., Karakiulakis G., Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? // Lancet. ‒ 11.03.2020.Fang L., Karakiulakis G., Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet, 11.03.2020.Forster P., Forster L., Renfrew C., Forster M. Phylogenetic network analysis of SARS-CoV-2 genomes. ‒ PNAS 08.04.2020.Forster P., Forster L., Renfrew C., Forster M. Phylogenetic network analysis of SARS-CoV-2 genomes. PNAS, 08.04.2020.Gautret et al. Hydroxychloroquine and azithromycin as a treatment of COVID‐19. 2020. https://www.dailykos.com/stories/2020/3/24/1930716/-Gautret-et-al-2020-Hydroxychloroquine-and-azithromycin-as-a-treatment-of-COVID-19.Gautret et al. Hydroxychloroquine and azithromycin as a treatment of COVID‐19. 2020. https://www.dailykos.com/stories/2020/3/24/1930716/-Gautret-et-al-2020-Hydroxychloroquine-and-azithromycin-as-a-treatment-of-COVID-19.Gautret P., Lagier J. C., Parola P., Hoang V. T. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study // Travel. Med. Infect. Dis. ‒ 2020. ‒ Apr 11:101663.Gautret P., Lagier J.C., Parola P., Hoang V.T. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Travel. Med. Infect. Dis., 2020, Apr 11:101663.Guo L., Ren L., Yang S., Xiao M. Profiling early humoral response to diagnose Novel Coronavirus Disease (COVID-19) // Clin. Infect. Dis. ‒ 2020. ‒ 21.03.2020. pii: ciaa310.Guo L., Ren L., Yang S., Xiao M. Profiling early humoral response to diagnose Novel Coronavirus Disease (COVID-19). Clin. Infect. Dis., 2020, 21.03.2020. pii: ciaa310.Han H., Luo Q., Mo F., Long L., Zheng W. SARS-CoV-2 RNA more readily detected in induced sputum than in throat swabs of convalescent COVID-19 patients // Lancet Infect. Dis. ‒ 12.03.2020. pii: S1473-3099(20)30174-2.Han H., Luo Q., Mo F., Long L., Zheng W. SARS-CoV-2 RNA more readily detected in induced sputum than in throat swabs of convalescent COVID-19 patients. Lancet Infect. Dis., 12.03.2020. pii: S1473-3099(20)30174-2.Hoffmann M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. ‒ Cell. 2020.Hoffmann M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell, 2020.Huang P. et al. Use of Chest CT in combination with negative RT-PCR assay for the 2019 Novel Coronavirus but high clinical suspicion // Radiology. ‒ 12.02.2020.Huang P. et al. Use of Chest CT in combination with negative RT-PCR assay for the 2019 Novel Coronavirus but high clinical suspicion. Radiology, 12.02.2020.Kim D., Lee J. Y., Yang J. S., Kim J. W., Kim V. N., Chang H. The architecture of SARS-CoV-2 transcriptome. ‒ bioRxiv. 15.03.2020.Kim D., Lee J.Y., Yang J.S., Kim J.W., Kim V.N., Chang H. The architecture of SARS-CoV-2 transcriptome. bioRxiv, 15.03.2020.Lan L., Xu D., Ye G., Xia C et al. Positive RT-PCR test results in patients recovered from COVID-19 // JAMA. ‒ 27.02.20.Lan L., Xu D., Ye G., Xia C et al. Positive RT-PCR test results in patients recovered from COVID-19. JAMA, 27.02.20.Lin L., Lu L., Cao W., Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection ‒ a review of immune changes in patients with viral pneumonia // Emerg. Microbes Infect. ‒ 2020. ‒ Mar 20. ‒ Р. 1-14.Lin L., Lu L., Cao W., Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection ‒ a review of immune changes in patients with viral pneumonia. Emerg. Microbes Infect., 2020, Mar 20, pp. 1-14.Pan F., Ye T., Sun P., Gui S. et al. Time course of lung changes on chest CT during recovery from 2019 Novel Coronavirus (COVID-19) pneumonia // Radiology. ‒ 2020.Pan F., Ye T., Sun P., Gui S. et al. Time course of lung changes on chest CT during recovery from 2019 Novel Coronavirus (COVID-19) pneumonia. Radiology, 2020.Pan Y., Zhang D., Yang P., Poon L. M., Wang Q. Viral load of SARS-CoV-2 in clinical samples // Lancet. ‒ 24.02.2020.Pan Y., Zhang D., Yang P., Poon L. M., Wang Q. Viral load of SARS-CoV-2 in clinical samples. Lancet, 24.02.2020.Paraskevis D. et al. Full-genome evolutionary analysis of the Novel Coronavirus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event // Infect. Genet. Evol. ‒ 28.01.2020.Paraskevis D. et al. Full-genome evolutionary analysis of the Novel Coronavirus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event. Infect. Genet. Evol., 28.01.2020.Pradhan P. et al. Uncanny similarity of unique inserts in the 2019-nCoV spike protein to HIV-1 gp120 and Gag. ‒ bioRhiv. 30.01.2020.Pradhan P. et al. Uncanny similarity of unique inserts in the 2019-nCoV spike protein to HIV-1 gp120 and Gag. bioRxiv, 30.01.2020.Qi F., Qian S., Zhang S., Zhang Z. Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses // Biochem. Biophys. Res. Commun. ‒ 18.03.2020.Qi F., Qian S., Zhang S., Zhang Z. Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses. Biochem. Biophys. Res. Commun., 18.03.2020.Richardson P., Griffin I., Tucker C., Smith D. et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease // Lancet. ‒ Vol. 395(10223). ‒ 2020.Richardson P., Griffin I., Tucker C., Smith D. et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet, vol. 395(10223), 2020.Salata C., Calistri A., Parolin C., Palù G. Coronaviruses: a paradigm of new emerging zoonotic diseases // Pathog. Dis. ‒ 2019. Dec. ‒ Vol. 77, № 9.Salata C., Calistri A., Parolin C., Palù G. Coronaviruses: a paradigm of new emerging zoonotic diseases. Pathog. Dis., 2019, Dec., vol. 77, no. 9.Shakiba Y. Application of desferal to treat COVID-19. https://clinicaltrials.gov/ct2/show/NCT04333550?cond=COVID-19&draw=2&rank=1.Shakiba Y. Application of desferal to treat COVID-19. https://clinicaltrials.gov/ct2/show/NCT04333550?cond=COVID-19&draw=2&rank=1.Shen C. et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma // JAMA. ‒ 2020.Shen C. et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA, 2020.Sheridan C. Fast, portable tests come online to curb coronavirus pandemic // Nat. Biotechnol. ‒ 2020. ‒ Mar 23.Sheridan C. Fast, portable tests come online to curb coronavirus pandemic. Nat. Biotechnol., 2020, Mar 23.Stebbing J. et al. COVID-19: Combining antiviral and anti-inflammatory treatments // Lancet Infect. Dis. ‒ 2020.Stebbing J. et al. COVID-19: Combining antiviral and anti-inflammatory treatments. Lancet Infect. Dis., 2020.Sun P., Lu X., Xu C., Wang Y., Sun W., Xi J. CD-sACE2 inclusion compounds: an effective treatment for Corona Virus Disease 2019 (COVID-19) // J. Med. Virol. ‒ 31.03.2020.Sun P., Lu X., Xu C., Wang Y., Sun W., Xi J. CD-sACE2 inclusion compounds: an effective treatment for Corona Virus Disease 2019 (COVID-19). J. Med. Virol., 31.03.2020.Tang N., Li D., Wang X., Sun Z. Abnormal Coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia // J. Thromb. Haemost. ‒ 2020. ‒ Vol. 18, № 4. ‒ Р. 844-847.Tang N., Li D., Wang X., Sun Z. Abnormal Coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J. Thromb. Haemost., 2020, vol. 18, no. 4, pp. 844-847.Veljkovic V., Vergara-Alert J., Segalés J., Paessler S. Use of the informational spectrum methodology for rapid biological analysis of the Novel Coronavirus 2019-nCoV: prediction of potential receptor, natural reservoir, tropism and therapeutic/vaccine target. F1000 Research. 31.01.2020.Veljkovic V., Vergara-Alert J., Segalés J., Paessler S. Use of the informational spectrum methodology for rapid biological analysis of the Novel Coronavirus 2019-nCoV: prediction of potential receptor, natural reservoir, tropism and therapeutic/vaccine target. F1000 Research, 31.01.2020.Wan S., Xiang Y., Fang W., Zheng Y. et al. Clinical features and treatment of COVID-19 patients in northeast chongqing // J. Med. Virol. ‒ 21.03.2020.Wan S., Xiang Y., Fang W., Zheng Y. et al. Clinical features and treatment of COVID-19 patients in northeast chongqing. J. Med. Virol., 21.03.2020.Wang M., Cao R., Zhang L., Yang X. Remdesivir and chloroquine effectively inhibit the recently emerged Novel Coronavirus (2019-nCoV) in vitro // Cell Research. ‒ 04.02.2020.Wang M., Cao R., Zhang L., Yang X. Remdesivir and chloroquine effectively inhibit the recently emerged Novel Coronavirus (2019-nCoV) in vitro. Cell Research, 04.02.2020.Wang Q., Qiu Y., Li J. Y., Zhou Z. J. et al. A unique protease cleavage site predicted in the spike protein of the Novel Pneumonia Coronavirus (2019-nCoV) potentially related to viral transmissibility // Virol. Sin. ‒ 2020 Mar 20.Wang Q., Qiu Y., Li J.Y., Zhou Z.J. et al. A unique protease cleavage site predicted in the spike protein of the Novel Pneumonia Coronavirus (2019-nCoV) potentially related to viral transmissibility. Virol. Sin., 20.03.2020.Wang W., Xu Y., Gao R., Lu R et al. Detection of SARS-CoV-2 in different types of clinical specimens // JAMA. ‒ 11.03.2020.Wang W., Xu Y., Gao R., Lu R et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA, 11.03.2020.Wenzhong L., Hualan L. COVID-19: Attacks the 1-Beta chain of hemoglobin and captures the porphyrin to inhibit human heme metabolism. ‒ ChemRxiv. 13.04.2020.Wenzhong L., Hualan L. COVID-19: Attacks the 1-Beta chain of hemoglobin and captures the porphyrin to inhibit human heme metabolism. ChemRxiv, 13.04.2020.Wit E., Feldmann F., Cronin J., Jordan R. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection // PNAS. ‒ 24.03.2020. ‒ Vol. 117, № 12. ‒ Р. 6771-6776.Wit E., Feldmann F., Cronin J., Jordan R. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. PNAS, 24.03.2020. vol. 117, no. 12, pp. 6771-6776.Wu A., Peng Y., Huang B., Ding X. et al. Genome composition and divergence of the Novel Coronavirus (2019-nCoV) originating in China // Cell. Host. Microbe. ‒ 07.02.20.Wu A., Peng Y., Huang B., Ding X. et al. Genome composition and divergence of the Novel Coronavirus (2019-nCoV) originating in China. Cell. Host. Microbe, 07.02.20.Xiao A. T., Tong Y. X., Gao C., Zhu L. Dynamic profile of RT-PCR findings from 301 COVID-19 patients in Wuhan, China: a descriptive study // J. Clin. Virol. ‒ 2020. ‒ Apr 11.Xiao A.T., Tong Y.X., Gao C., Zhu L. Dynamic profile of RT-PCR findings from 301 COVID-19 patients in Wuhan, China: a descriptive study. J. Clin. Virol., 2020, Apr 11.Xiong Y. et al. Clinical and high-resolution CT features of the COVID-19 infection: comparison of the initial and follow-up changes // Invest. Radiol. ‒ 2020. ‒ AJR Am. J. Roentgenol. ‒ 2020.Xiong Y. et al. Clinical and high-resolution CT features of the COVID-19 infection: comparison of the initial and follow-up changes. Invest. Radiol., 2020, AJR Am. J. Roentgenol., 2020.Yamamoto N., Matsuyama S., Hoshino T., Yamamoto N. Nelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro. ‒ bioRxiv. 2020.Yamamoto N., Matsuyama S., Hoshino T., Yamamoto N. Nelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro. bioRxiv, 2020.Yang M. Cell pyroptosis, a potential pathogenic mechanism of 2019-nCoV infection // SSRN: https://ssrn.com/abstract=3527420, 29.01.2020.Yang M. Cell pyroptosis, a potential pathogenic mechanism of 2019-nCoV infection. SSRN: https://ssrn.com/abstract=3527420, 29.01.2020.Yao X., Ye F., Zhang M., Cui C., Huang B., Niu P. et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) // Clin. Infect. Dis. ‒ 2020.Yao X., Ye F., Zhang M., Cui C., Huang B., Niu P. et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis., 2020.Yi H. 2019 novel coronavirus is undergoing active recombination // Clin. Infect. Dis. ‒ 2020.Yi H. 2019 novel coronavirus is undergoing active recombination. Clin. Infect. Dis., 2020.Yu F., Yan L., Wang N., Yang S. Quantitative detection and viral load analysis of SARS-CoV-2 in infected patients // Clin. Infect. Dis. ‒ 28.03.2020, pii: ciaa345.Yu F., Yan L., Wang N., Yang S. Quantitative detection and viral load analysis of SARS-CoV-2 in infected patients. Clin. Infect. Dis., 28.03.2020, pii: ciaa345.Zhang L., Lin D., Kusov Y., Nian Y. et al. Alpha-ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication Structure-based design, synthesis, and activity assessment // J. Med. Chem. ‒ 11.02.2020.Zhang L., Lin D., Kusov Y., Nian Y. et al. Alpha-ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication Structure-based design, synthesis, and activity assessment. J. Med. Chem., 11.02.2020.Zhang T., Wu Q., Zhang Z. Probable pangolin origin of SARS-CoV-2 associated with the COVID-19 outbreak // Curr. Biol. ‒ 13.03.2020.Zhang T., Wu Q., Zhang Z. Probable pangolin origin of SARS-CoV-2 associated with the COVID-19 outbreak. Curr. Biol., 13.03.2020.Zhang W., Zhao Y., Zhang F., Wang Q. et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The experience of clinical immunologists from China // Clin. Immunology. – 2020. – Р. 108393.Zhang W., Zhao Y., Zhang F., Wang Q. et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The experience of clinical immunologists from China. Clin. Immunology, 2020, pp. 108393.Zhao J. et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. – 2020.Zhao J. et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. 2020.Zhao W., Zhong Z., Xie, Yu Q., Liu J. Relation between chest CT findings and clinical conditions of coronavirus disease (COVID-19) pneumonia: A multicenter study.Zhao W., Zhong Z., Xie, Yu Q., Liu J. Relation between chest CT findings and clinical conditions of coronavirus disease (COVID-19) pneumonia: A multicenter study.Zhao Y., Zhao Z., Wang Y., Zhou Y., Ma Y., Zuo W. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. ‒ bioRxiv. 26.01.2020.Zhao Y., Zhao Z., Wang Y., Zhou Y., Ma Y., Zuo W. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. bioRxiv, 26.01.2020.Zou L., M. Sc. et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients // New Engl. J. Med. ‒ 20.02.20.Zou L., M. Sc. et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. New Engl. J. Med., 20.02.20.

The authors declare that there are no conflicts of interest present.